TUESDAY, Oct. 22, 2019 -- A new drug to treat most cystic fibrosis patients has been approved by the U.S. Food and Drug Administration.
Trikafta (elexacaftor/ivacaftor/tezacaftor) is the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation. Its list price is $311,000 a year, same as one of the maker's earlier treatments for the genetic disease.
THURSDAY, Sept. 26, 2019 -- More U.S. children today have developmental disabilities like autism and ADHD than a decade ago, though improved recognition may be a major reason, according to a government study.
Researchers found that between 2009 and 2017, the percentage of U.S. children and teens with a developmental disability rose from just over 16% to nearly 18%. Increases in ADHD (attention deficit hyperactivity disorder) and autism spectrum disorders accounted for most of the change.